Alexandre G. Leclercq

arXiv2026

CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction, disease progression modelling, and personalized medicine. We present CFB-GBM v2.0, an extension of our previously released CFB-GBM dataset comprising 264 GBM patients treated according to the standard Stupp protocol. The primary contribution of this release is the completion of Gross Tumour Volume (GTV) delineations across all available timepoints ($t_0$, $t_1$ and $t_2$), increasing the overall GTV completion rate from 35% to 97%. This was achieved using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on CFB-GBM ground-truth contours, with the generated segmentations validated by five radiation oncologists. From these longitudinal GTV annotations, volumetric RANO 2.0 response category labels were derived for all available temporality pairs ($t_0 \rightarrow t_1$, $t_0 \rightarrow t_2$ and $t_1 \rightarrow t_2$). To further ease dataset usability and reproducibility, brain masks computed with HD-BET and pre-computed radiomic features extracted with PyRadiomics are provided for each patient timepoint and MRI modality. Additionally, the WHO classification guideline (2016 vs. 2021) applicable to each patient's diagnosis is now explicitly documented. CFB-GBM v2.0 is publicly available on The Cancer Imaging Archive (TCIA) at https://www.cancerimagingarchive.net/collection/cfb-gbm .

cs.CV↗

arXiv2025

Pre to Post-Treatment Glioblastoma MRI Prediction using a Latent Diffusion Model

Glioblastoma (GBM) is an aggressive primary brain tumor with a median survival of approximately 15 months. In clinical practice, the Stupp protocol serves as the standard first-line treatment. However, patients exhibit highly heterogeneous therapeutic responses which required at least two months before first visual impact can be observed, typically with MRI. Early prediction treatment response is crucial for advancing personalized medicine. Disease Progression Modeling (DPM) aims to capture the trajectory of disease evolution, while Treatment Response Prediction (TRP) focuses on assessing the impact of therapeutic interventions. Whereas most TRP approaches primarly rely on timeseries data, we consider the problem of early visual TRP as a slice-to-slice translation model generating post-treatment MRI from a pre-treatment MRI, thus reflecting the tumor evolution. To address this problem we propose a Latent Diffusion Model with a concatenation-based conditioning from the pre-treatment MRI and the tumor localization, and a classifier-free guidance to enhance generation quality using survival information, in particular post-treatment tumor evolution. Our model were trained and tested on a local dataset consisting of 140 GBM patients collected at Centre François Baclesse. For each patient we collected pre and post T1-Gd MRI, tumor localization manually delineated in the pre-treatment MRI by medical experts, and survival information.

cs.CV↗